
EQT exits Schuelke to Athos-led consortium
EQT has sold infection specialist Schuelke to a consortium led by family office Athos, in one of the first large-cap private equity healthcare deals to get over the line this year.
The deal gave the company a EUR 1.4bn price tag for the asset, according to media reports.
The Athos family office manages the wealth of brothers Andreas and Thomas Struengmann, who were early backers of BioNTech prior to its vaccine partnership with Pfizer. Other co-investors, including Bitburger Holding, are joining the ticket, EQT said.
Athos also co-invested when EQT moved Swiss drug delivery manufacturer SHL Medical to a longer-term investment strategy.
EQT said in a statement that it delivered double-digit annual growth and almost doubled the EBITDA of the core healthcare business over its holding period.
It tapped Bank of America in 2Q23 to oversee a highly anticipated exit, just three years after it first acquired the asset via a carve-out from Air Liquide for around EUR 1bn.
The sellside was marketing the asset off EBITDA of roughly EUR 100m, as reported.
EQT held the asset via the 2018-vintage EQT VIII, which is already significantly realised compared to other vehicles of the same period. It has already partially exited Azelis and SUSE via IPO, in addition to moving SHL Medical to its long-term fund.
The quick-flip window goes against the grain at a time when holding periods are elongating and other large-cap auctions in the healthcare space have thus far failed to materialise in an exit.
Company
Headquartered in Norderstedt, Schuelke supplies hospitals and other healthcare institutions with high-quality disinfectants and antisepsis products. It also sells to the pharmacy and direct patient care channels, as well as the global life science industry. It employs around 1,200 people and generates sales in more than 80 countries.
People
EQT - Matthias Wittkowski (partner).
Schuelke - Stefan Kukacka (CEO).
Advisors
Vendor - Bank of America (M&A); Freshfields (legal); Deloitte (tax, financial); Bain & Company (commercial).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater